Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy - Judge, Daniel P.; Heitner, Stephen B.; Falk, Rodney H.; Maurer, Mathew S.; Shah, Sanjiv J.; Witteles, Ronald M.; Grogan, Martha; Selby, Van N.; Jacoby, Daniel; Hanna, Mazen; Nativi-Nicolau, Jose; Patel, Jignesh; et al. (Journal of the American College of Cardiology, 2019)
Keywords: AG10; Aged; Aged, 80 and over; Aging; Amyloid Neuropathies, Familial - diagnosis; Amyloid Neuropathies, Familial - drug therapy; Amyloidosis; ATTR-CM; Benzoates - pharmacology; Benzoates - therapeutic use; Binding sites; Cardiology; Cardiomyopathy; Cardiovascular; Chronic illnesses; Clinical trials; Double-Blind Method; Female; Fluorescent indicators; Heart diseases; Heart failure; Heart Failure - diagnosis; Heart Failure - drug therapy; Humans; Hydrogen bonds; Male; Middle Aged; Mortality; Mutation; Patients; Pharmacodynamics; Pharmacokinetics; Plasma levels; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; Transthyretin; heart failure; amyloidosis; NT-proBNP; TTR; transthyretin; ATTR-CM; FPE; AG10; cardiomyopathy; N-terminal pro-brain type natriuretic peptide; fluorescent probe exclusion; transthyretin amyloid cardiomyopathy